Liquid chromatography-tandem mass spectrometry method for the simultaneous determination of δ-ALA, tyrosine and creatinine in biological fluids

Clinica Chimica Acta

Volumn 350, Issue 1-2, 2004, Pages 219-230

  Felitsyn, Natalia M ^a   Henderson, George N ^a   James, Margaret O ^b   Stacpoole, Peter W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

aminolevulinic acid; Creatinine; HPLC; Tandem mass spectrometry; Tyrosine; Urine

Indexed keywords

2 (2 NITRO 4 TRIFLUOROMETHYLBENZYL) 1,3 CYCLOHEXANEDIONE; AMINOLEVULINIC ACID; CREATININE; CYCLOHEXANE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BODY FLUID; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERIVATIZATION; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TYROSINEMIA; URINALYSIS; URINE LEVEL;

AMINOLEVULINIC ACID; CALIBRATION; CHROMATOGRAPHY, LIQUID; CREATININE; CYCLOHEXANONES; ENZYME INHIBITORS; HUMANS; MASS SPECTROMETRY; NITROBENZOATES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TYROSINE;

EID: 7644237493     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.08.009     Document Type: Article

References (42)

1. Y. Duydu, and N. Vural Urinary excretion of lead and delta-aminolevulinic acid in workers occupationally exposed to tetraethyl lead Biol. Trace Elem. Res. 63 1998 185 194
2. V. Horsawad, P. Pongpaew, and R. Tungtrongchitr Lead exposure, urinary delta-aminolevulinic acid concentrations and haematological parameters of road sweepers working in congested areas of Bangkok J. Nutr. Environ. Med. 9 1999 109 114
3. B.M. Solliway, A. Schaffer, H. Pratt, and S. Yannai Effects of exposure to lead on selected biochemical and haematological variables Pharmacol. Toxicol. 78 1996 18 22
4. Y. Nordmann, and H. Puy Human hereditary hepatic porphyrias Clin. Chim. Acta 325 2002 17 37
5. R.D. Ellefson, and R.E. Ford The porphyrias [corrected]: characteristics and laboratory tests Regul. Toxicol. Pharmacol. 24 Pt2 1996 S119 S125
6. S.T. Pitkanen, M.K. Salo, and M. Heikinheimo Hereditary tyrosinemia type I: from basics to progress in treatment Ann. Med. 32 2000 530 538
7. E. Pronicka, Z. Meielniczuk, and E. Rowinska Urinary succinylacetone presence and delta-aminolevulinic acid excretion in patients with type I tyrosinaemia during treatment Mater. Med. Pol. 23 1991 136 138
8. E. Christensen, B.B. Jacobsen, and N. Gregersen Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia Clin. Chim. Acta 116 1981 331 341
9. H. Schierbeek, G.J. Beukeveld, and H. van Faassen Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and δ-aminolevulinic acid J. Inherit. Metab. Dis. 16 1993 1034 1040
10. M. Karbownik, D. Tan, L.C. Manchester, and R.J. Reiter Renal toxicity of the carcinogen delta-aminolevulinic acid: antioxidant effects of melatonin Cancer Lett. 161 2000 1 7
11. M.E. Rocha, F. Dutra, and B. Bandy Oxidative damage to ferritin by 5-aminolevulinic acid Arch. Biochem. Biophys. 409 2003 349 356
12. R.C. Carneiro, and R.J. Reiter Delta-aminolevulinic acid-induced lipid peroxidation in rat kidney and liver is attenuated by melatonin: an in vitro and in vivo study J. Pineal Res. 24 1998 131 136
13. C.A. Costa, G.C. Trivelato, A.M. Pinto, and E.J. Bechara Correlation between plasma 5-aminolevulinic acid concentrations and indicators of oxidative stress in lead-exposed workers Clin. Chem. 43 1997 1196 1202
14. Y. Hiraku, and S. Kawanishi Mechanism of oxidative DNA damage induced by delta-aminolevulinic acid in the presence of copper ion Cancer Res. 56 1996 1786 1793
15. M. Demasi, C.A. Penatti, R. DeLucia, and E.J. Bechara The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias Free Radic. Biol. Med. 20 1996 291 299
16. J. Onuki, P.C. Teixeira, and M.H. Medeiros Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria? Cell. Mol. Biol. 48 1 2002 17 26
17. J.J. Schuitmaker, P. Baas, H.L. van Leengoed, F.W. van der Meulen, W.M. Star, and N. van Zandwijk Photodynamic therapy: a promising new modality for the treatment of cancer J. Photochem. Photobiol. B 34 1996 3 12
18. S.L. Marcus, R.S. Sobel, A.L. Golub, R.L. Carroll, S. Lundahl, and D.G. Shulman Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status J. Clin. Laser Med. Surg. 14 1996 59 66
19. A. Casas, and A. Batlle Rational design of 5-Aminolevulinic acid derivatives aimed at improving photodynamic therapy Curr. Med. Chem. Anti-Canc. Agents 2 2002 465 475
20. D.C. Shackley, C. Briggs, and A. Gilhooley Photodynamic therapy for superficial bladder cancer under local anaesthetic BJU Int. 89 2002 665 670
21. J. Fuchs, S. Weber, and R. Kaufmann Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy Free Radic. Biol. Med. 28 2000 537 548
22. D. Mauzerall, and S. Granick The occurrence and determination of δ-aminolevulinic acid and porphobilinogen in urine J. Biol. Chem. 219 1956 435 446
23. E.I. Minder Measurement of 5-aminolaevulinic acid by reversed phase HPLC and fluorescence detection Clin. Chim. Acta 161 1986 11 18
24. A. Okayama, S. Fujii, and R. Miura Optimized fluorometric determination of urinary delta-aminolevulinic acid by using pre-column derivatization, and identification of the derivative Clin. Chem. 36 Pt 1 1990 1494 1497
25. Y. Endo, A. Okayama, G. Endo, T. Ueda, N. Nakazono, and S. Horiguchi Improvement of urinary delta-aminolevulinic acid determination by HPLC and fluorescence detection using condensing reaction with acetylacetone and formaldehyde. Sangyo Igaku (Japanese Journal of Industrial Health) 36 1994 49 56
26. H. Oishi, H. Nomiyama, K. Nomiyama, and K. Tomokuni Fluorimetric HPLC determination of δ-aminolevulinic acid (ALA) in the plasma and urine of lead workers: biological indicators of lead exposure J. Anal. Toxicol. 20 1996 106 110
27. Y. Morita, S. Araki, T. Sakai, and Y. Masuyama Determination of delta-aminolevulinic acid in plasma using high-performance liquid chromatography: a sensitive indicator of lead effects Ind. Health 32 1994 85 96
28. R. Kauppinen, and M. Von und Zu Fraunberg Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families Clin. Chem. 48 2002 1891 1900
29. K. Tomokuni, M. Ichiba, Y. Hirai, K. Sugimoto, T. Yoshida, and M. Hirata Comparison between the fluorimetric HPLC method and the conventional method for determining urinary delta-aminolevulinic acid and coporphyrin as indices of lead exposure Int. Arch. Occup. Environ. Health 61 1988 153 156
30. C.A. Costa, G.C. Trivelato, M. Demasi, and E.J. Bechara Determination of 5-aminolevulinic acid in blood plasma, tissues and cell cultures by high performance liquid chromatography with electrochemical detection J. Chromatogr. B Biomed. Sci. Appl. 695 1997 245 250
31. A. Gorchein Determination of delta-aminolaevulinic acid in biological fluids by gas-liquid chromatography with electron-capture detection Biochem. J. 219 1984 883 889
32. A. Bunke, H. Schmid, G. Burmeister, H.P. Merkle, and B. Gander Validation of a capillary electrophoresis method for determination of 5-aminolevulinic acid and degradation products J. Chromatogr. A 883 2000 285 290
33. G.A. Lord, J.L. Luo, and C.K. Lim Capillary zone electrophoresis/mass spectrometry of 5-aminolaevulinic acid and porphobilinogen Rapid Commun. Mass Spectrom. 14 2000 314 316
34. P. Sithisarankul, B.S. Schwartz, B.K. Lee, and P.T. Strickland Urinary 5-aminolevulinic acid (ALA) adjusted by creatinine: a surrogate for plasma ALA? J. Occup. Environ. Med. 40 1998 901 906
35. A. Hudak, G. Kiss, M. Naray, and E. Süveges Evaluation of delta-aminolaevulinic acid excretion in random urine samples of children Eur. J. Pediatr. 153 1994 187 189
36. K. Paradis Tyrosinemia: the Quebec experience Clin. Invest. Med. 19 1996 311 316
37. J. Laine, M.K. Salo, K. Krogerus, J. Kärkkäinen, O. Wahlroos, and C. Holmber The nephropathy of type I tyrosinemia after liver transplantation Pediatr. Res. 37 1995 640 645
38. S. Forget, H.B. Patriquin, and J. Dubois The kidney in children with tyrosinemia: sonographic, CT and biochemical findings Pediatr. Radiol. 29 1999 104 108
39. C.A. Burtis E.R. Ashwood Tietz textbook of clinical chemistry 3rd ed. 1999 WB Saunders Philadelphia (1243-1245 pp.)
40. A. Namera, M. Yashiki, M. Nishida, and T. Kojima Direct extract derivatization for determination of amino acids in human urine by gas chromatography and mass spectrometry J. Chromatogr. B 776 2002 49 55
41. A.L. Shroads, G.N. Henderson, J. Cheung, M.O. James, and P.W. Stacpoole Unified gas chromatographic-mass spectrometric method for quantitating tyrosine metabolites in urine and plasma J. Chromatogr. B 808 2004 153 161
42. H. Orhan, N.P. Vermeulen, C. Tump, H. Zappey, and J.H. Meerman Simultaneous determination of tyrosine, phenylalanine and deoxyguanosine oxidation products by liquid chromatography-tandem mass spectrometry as noninvasive biomarkers for oxidative damage J. Chromatogr. B 799 2004 245 254